Published in

American Association for the Advancement of Science, Science Advances, 3(5), 2019

DOI: 10.1126/sciadv.aav6322

Links

Tools

Export citation

Search in Google Scholar

Hybrid nanocarriers incorporating mechanistically distinct drugs for lymphatic CD4+ T cell activation and HIV-1 latency reversal

Journal article published in 2019 by Shijie Cao ORCID, Sarah D. Slack ORCID, Claire N. Levy ORCID, Sean M. Hughes ORCID, Yonghou Jiang, Christopher Yogodzinski, Pavitra Roychoudhury ORCID, Keith R. Jerome ORCID, Joshua T. Schiffer ORCID, Florian Hladik ORCID, Kim A. Woodrow ORCID
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Red circle
Postprint: archiving forbidden
Green circle
Published version: archiving allowed
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

Targeted nanocarriers deliver HIV-1 latency-reversing agents to CD4 + T cells in the lymph nodes.